Investment Thesis
AtaiBeckley is an early-stage pharmaceutical company with exceptional revenue growth (+1228% YoY) but from a near-zero base ($954K annually), paired with massive operating losses (-$30.9M) creating an unsustainable burn rate. While the balance sheet is strong with $43.1M cash, zero debt, and 10x liquidity ratios, current cash burn of $21.1M annually provides only ~2 years of runway before requiring additional financing or achieving profitability.
Strengths
- Exceptional revenue growth rate of 1227.6% year-over-year demonstrates early commercialization momentum
- Fortress balance sheet with $198.7M stockholders equity, zero long-term debt, and 10.02x current ratio providing significant financial flexibility
- Strong cash position of $43.1M with minimal leverage provides runway for development
Risks
- Unsustainable cash burn of $21.1M annually against minimal revenue of $954K results in negative operating margin of -3239%, indicating massive operating inefficiency
- Cash reserves of $43.1M at current burn rate provide only ~2 years of funding, requiring near-term achievement of profitability or significant additional capital raises
- Extreme losses with -$29.8M net income and -3121.8% net margin indicate fundamental business model challenges in pharmaceutical sector with uncertain path to profitability
- Limited revenue base creates execution risk; high growth rate from near-zero may not be sustainable
Key Metrics to Watch
- Operating cash burn trajectory and cash runway extension
- Revenue growth sustainability and gross margin achievement
- Path to operating profitability and quarterly cash burn improvement
Financial Metrics
Revenue
954.0K
Net Income
-29.8M
EPS (Diluted)
$-0.08
Free Cash Flow
-21.1M
Total Assets
264.9M
Cash
43.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-3,239.1%
Net Margin
-3,121.8%
ROE
-15.0%
ROA
-11.2%
FCF Margin
-2,210.7%
Balance Sheet & Liquidity
Current Ratio
10.02x
Quick Ratio
10.02x
Debt/Equity
0.00x
Debt/Assets
25.0%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:42:17.290641 |
Data as of: 2026-03-31 |
Powered by Claude AI